Idenix Clinical Hold On Two Hep C Programs May Be Resolved By Year-End
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Serious adverse events that triggered an FDA clinical hold on two of Idenix's hepatitis C programs - IDX184 and IDX320 - could have been caused by an unforeseen effect of combining the drugs, as opposed to a defect with one of the individual drugs
You may also be interested in...
Active Deal-Making Year Anticipated In HCV As New, Better Drug Combos Emerge
Following the European Association for the Study of the Liver's annual meeting this past week in Vienna, Austria, it became clear that most companies active in the hepatitis C space hope to be part of the current best hope for HCV therapy: a once-daily, oral cocktail of antiviral drugs that will replace the current standard of care
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product